首页> 外文OA文献 >A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

【2h】

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

机译：阿维菌素（BIBW 2992）是一种不可逆的ErbB家族阻滞剂的II期研究，用于治疗HER2阳性转移性乳腺癌后曲妥珠单抗治疗的患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Nancy U. Lin; Eric P. Winer; Duncan Wheatley; Lisa A. Carey; Stephen Houston; David Mendelson; Pamela Munster; Laurie Frakes; Steve Kelly; Agustin A. Garcia; Susan Cleator; Martina Uttenreuther-Fischer; Hilary Jones; Sven Wind; Richard Vinisko; Tamas Hickish; Lin, Nancy U.;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab [J] . LinN.U., WinerE.P., WheatleyD., Breast cancer research and treatment. . 2012,第3期

机译：afatinib（BIBW 2992）（一种不可逆的ErbB家族阻滞剂）在HER2阳性转移性乳腺癌患者曲妥珠单抗治疗后进展的II期研究
2. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab [J] . Nancy U. Lin, Eric P. Winer, Duncan Wheatley, Breast Cancer Research and Treatment . 2012,第3期

机译：afatinib（BIBW 2992），一种不可逆的ErbB家族阻滞剂，在曲妥珠单抗后进展为HER2阳性转移性乳腺癌的患者中进行II期研究
3. HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. [J] . Modi S, Stopeck A, Linden H, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第15期

机译：HSP90抑制作用在乳腺癌中有效：在曲妥珠单抗上进展的HER2阳性转移性乳腺癌患者中，坦西霉素（17-AAG）加曲妥珠单抗的II期试验。
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. A phase II study of afatinib (BIBW 2992) an irreversible ErbB family blocker in patients with HER2-positive metastatic breast cancer progressing after trastuzumab [O] . Nancy U. Lin, Eric P. Winer, Duncan Wheatley, -1

机译：afatinib（BIBW 2992）一种不可逆的ErbB家族阻滞剂在曲妥珠单抗后进展为HER2阳性转移性乳腺癌的患者中进行II期研究
7. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab [O] . Nancy U. Lin, Eric P. Winer, Duncan Wheatley, 2012

机译：afatinib（BIBW 2992），一种不可逆的ErbB家族阻滞剂，在曲妥珠单抗后进展为HER2阳性转移性乳腺癌的患者中进行II期研究

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

著录项

相似文献

相关主题

期刊订阅